Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Taichengsi (Shanghai) Biopharmaceutical
Shanghai, Shanghai Shi, Chinaaxcynsis.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Taichengsi is developing preclinical antibody-drug conjugates and monoclonal antibodies targeting Claudin 6 and other tumor-associated proteins, primarily for cancer indications; no clinical results reported as of July 2025
- Therapeutic areas
- OncologyEndocrinologyHematologyGastroenterology
- Modalities
- Antibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
02
Partnerships
No public partnerships with major pharmaceutical companies disclosed as of July 2025
Beyond the preview
Go deeper on Taichengsi (Shanghai) Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taichengsi (Shanghai) Biopharmaceutical.